Like any medical field, obesity medicine continues to evolve to meet the needs of its patients. GLP-1 therapies have been opening up new possibilities for people managing weight-related issues and Type 2 diabetes. With new formulas and variations, it’s important to understand what treatment plan is best for you. Whether you’re considering weight loss medications, dealing with weight-related issues, or seeking treatment for Type 2 diabetes, knowledge is key. This week on Fox17, Dr. Egan breaks down what GLP-1 medication is and the exciting new advancements coming.
Fact #1
GLP-1 medications mimic the effects of the body’s natural hormone, glucagon-like peptide-1 (GLP-1). This hormone plays a key role in the incretin system, helping regulate blood sugar levels and appetite. These medications are primarily used to treat Type 2 diabetes, obesity, and overweight conditions, including obstructive sleep apnea and cardiovascular disease. They go by the brand names Ozempic®, Wegovy®, Mounjaro®, and Zepbound®.
Fact #2
GLP-1 medications are most effective when injected. When taken orally, the peptides are broken down by digestive enzymes in the stomach and intestines and do not survive long enough to be absorbed into the bloodstream. When injected, the peptides can bypass the digestive system and bind to the GLP-1 receptors. The current oral version requires a special absorption enhancer and strict guidelines to effectively work.
Fact #3
Advances in drug formulas are overcoming barriers in the oral version. Novo Norodisk’s oral semaglutide (Rybelsus®) has demonstrated that with the right technology, oral GLP-1 drugs can be effective. There is ongoing research testing new formulas that decrease food and timing restrictions and include advances such as absorption enhancers and protective coatings. As technology evolves, it’s hopeful that oral GLP-1 therapies will be an alternative to injections, expanding their accessibility.
Fact #4
New variations of GLP-1 medications continue to emerge. Eli Lilly’s oral GLP-1 drug, orforglipron, is expected to launch in the U.S. in 2026, pending approval for treatment of weight management and Type 2 diabetes. Orforglipron is a once-daily, small-molecule GLP-1 receptor agonist that showed strong results in clinical trials, including 8% weight loss over 40 weeks. Unlike other oral versions medications, it has no food or water restrictions. The company is preparing to meet the expected high demand by building a large supply before launch to help ensure patient access.
Takeaway Tip:
GLP-1s offer powerful benefits and hope for individuals with obesity or Type 2 diabetes. At true., we encourage everyone considering weight loss medication or contemplating next steps to work with a medical professional. It’s essential to take control of your health by seeking expert guidance and listening to science-backed information.